Eden Research plc Director/PDMR Shareholding (5923U)

TIDMEDEN

RNS Number : 5923U

Eden Research plc

13 July 2018

13 July 2018

Eden Research plc

("Eden" or "Company)

Director/PDMR Shareholding

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has today purchased 92,848 ordinary shares of 1p in Eden ("Ordinary Shares") and Alex Abrey, CFO, has sold 125,000 Ordinary Shares and at the same time purchased 179,664 Ordinary Shares through his Self-Invested Personal Pension (SIPP).

Following the transactions outlined above, Mr Smith holds 306,769 Ordinary Shares representing 0.15 per cent. of the Company's issued share capital and Mr Abrey holds 1,102,824 Ordinary Shares representing 0.53 per cent. of the Company's issued share capital.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details of the PDMR dealings set out above.

 
 1      Details of the person discharging managerial responsibilities / person closely associated 
 a)     Name                                                     Mr Sean Smith 
       -------------------------------------------------------  ------------------------------------------------------ 
 2      Reason for the notification 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Position/status                                          Chief Executive Officer 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     Initial notification /Amendment                          Initial notification 
       -------------------------------------------------------  ------------------------------------------------------ 
 3      Details of the issuer, emission allowance market participant, auction platform, auctioneer 
         or auction monitor 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Name                                                     Eden Research plc 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     LEI                                                      213800ZWTYTVQQSM3J85 
       -------------------------------------------------------  ------------------------------------------------------ 
 4      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
         each type of transaction; (iii) each date; and (iv) each place where transactions have been 
         conducted 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Description of the financial instrument, type of         Ordinary shares of 1 pence each in the Company 
        instrument                                               ("Ordinary Shares") 
 
        Identification code                                      GB0001646941 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     Nature of the transaction                                Purchase of Ordinary Shares 
       -------------------------------------------------------  ------------------------------------------------------ 
 
                                                                    Price(s)           Volume(s) 
 
   c)     Price(s) and volume(s)                                     11.90 pence per    92,848 Ordinary 
                                                                     share              Shares 
                                                                                      ----------------- 
       -------------------------------------------------------  ------------------------------------------------------ 
 d)     Aggregated information 
 
         - Aggregated volume 
                                                                   N/A (single transaction) 
         - Price 
       -------------------------------------------------------  ------------------------------------------------------ 
 e)     Date of the transaction                                  13/7/2018 
       -------------------------------------------------------  ------------------------------------------------------ 
 f)     Place of the transaction                                 LSE, AIM Market (XLON) 
       -------------------------------------------------------  ------------------------------------------------------ 
 
 
 1      Details of the person discharging managerial responsibilities / person closely associated 
 a)     Name                                                     Mr Alex Abrey 
       -------------------------------------------------------  ------------------------------------------------------ 
 2      Reason for the notification 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Position/status                                          Chief Financial Officer 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     Initial notification /Amendment                          Initial notification 
       -------------------------------------------------------  ------------------------------------------------------ 
 3      Details of the issuer, emission allowance market participant, auction platform, auctioneer 
         or auction monitor 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Name                                                     Eden Research plc 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     LEI                                                      213800ZWTYTVQQSM3J85 
       -------------------------------------------------------  ------------------------------------------------------ 
 4      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
         each type of transaction; (iii) each date; and (iv) each place where transactions have been 
         conducted 
       --------------------------------------------------------------------------------------------------------------- 
 a)     Description of the financial instrument, type of         Ordinary shares of 1 pence each in the Company 
        instrument                                               ("Ordinary Shares") 
 
        Identification code                                      GB0001646941 
       -------------------------------------------------------  ------------------------------------------------------ 
 b)     Nature of the transaction                                (1) Sale of Ordinary Shares 
                                                                  (2) Purchase of Ordinary Shares 
       -------------------------------------------------------  ------------------------------------------------------ 
 
                                                                   (1) Sale Price(s)           Volume(s) 
 
   c)     Price(s) and volume(s)                                     11.60 pence per    125,000 Ordinary 
                                                                     share              Shares 
                                                                                      ------------------ 
 
 
                                                                   (2) Purchase Price(s)           Volume(s) 
 
                                                                     12.22 pence per    179,664 Ordinary 
                                                                     share              Shares 
                                                                                      ------------------ 
       -------------------------------------------------------  ------------------------------------------------------ 
 d)     Aggregated information 
 
         - Aggregated volume 
                                                                   N/A (single transactions) 
         - Price 
       -------------------------------------------------------  ------------------------------------------------------ 
 e)     Date of the transaction                                  13/7/2018 
       -------------------------------------------------------  ------------------------------------------------------ 
 f)     Place of the transaction                                 LSE, AIM Market (XLON) 
       -------------------------------------------------------  ------------------------------------------------------ 
 

For further information contact:

 
 Eden Research plc                  www.edenresearch.com 
 Sean Smith 
  Alex Abrey                        01285 359 555 
 
 Shore Capital (Nomad)              020 7408 4090 
 Stephane Auton / Patrick Castle 
 
 Powerscourt (Financial PR)         020 7250 1446 
 Nick Dibden 
 

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer products industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of GBP13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHSFUSUDFASEFW

(END) Dow Jones Newswires

July 13, 2018 05:23 ET (09:23 GMT)